Neuphoria Therapeutics Inc (Nasdaq:NEUP), a late-stage biotechnology developing treatments for neuropsychiatric disorders, said on Wednesday that it will receive a USD15m milestone payment from US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, following the initiation of a Phase 2 clinical trial for MK-1167 in Alzheimer's disease.
The trial, evaluating the safety and efficacy of MK-1167 as an α7 nicotinic acetylcholine receptor positive allosteric modulator, is the second milestone achieved in the partnership.
Neuphoria's collaboration with Merck focuses on developing treatments for neuropsychiatric disorders, with the company eligible for up to USD450m in additional milestone payments. The agreement also includes royalties on net sales of any licensed products.
This payment reflects the progress of MK-1167 in advancing towards potential therapeutic use in Alzheimer's disease dementia.
Immunome initiates Phase 1 trial of ROR1-targeted ADC IM-1021
Arrowhead Pharmaceuticals reports positive topline results for ARO-C3 in IgA nephropathy trial
Celltrion's OMLYCLO receives US FDA approval
RiboX Therapeutics doses first patient in RXRG001 first-in-human Phase I/IIa clinical trial
Doer Bio completes DR10624phase two clinical study enrolment
Health Canada approves ALK's ACARIZAX for young children with dust mite allergy
Kancera and Recardio sign letter of intent for licensing agreement
Bantam Pharmaceutical expands Phase 1 trial of BTM-3566 into Canada
Integral Molecular reports first patient dosed in CTIM-76 Phase 1 clinical trial
Plus Therapeutics secures FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda
CStone Pharmaceuticals submits Phase Ib clinical trial application for CS5001 in Australia
Akeso completes patient enrolment for cadonilimab Phase III registrational clinical trial
Jazz Pharmaceuticals to acquire Chimerix in USD935m deal to expand oncology portfolio